Drug Delivery Partnering Terms and Agreements is a new market research publication announced by Reportstack. This report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 2,000 links to online copies of actual drug delivery deals and contract documents where available as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The drug delivery technology includes the following sub-technology areas:
Drug Delivery
Bioavailability
Implanatable
Oral delivery
Rapid release
Delayed release
Parenteral
Infusion
Injectable
Pro-drug
Targeted
Tropical
Transdermal
Buccal
Inhaled
Nasal
Ocular
Rectal
Sublingual
Urogenital
The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in drug delivery dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms. Chapter 2 also contains case studies providing an insight into how companies enter into drug delivery dealmaking.
Chapter 3 provides a review of the leading drug delivery deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and the contract document, providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of drug delivery partnering deals organized by specific drug delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in drug delivery partnering and dealmaking since 2009.
In addition, a comprehensive appendix is provided organized by drug delivery partnering company A-Z, deal type definitions and drug delivery partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of drug delivery technologies and products.
Drug Delivery Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to drug delivery trends and structure of deals entered into by leading companies worldwide.
Drug Delivery Partnering Terms and Agreements includes:
Trends in drug delivery dealmaking in the biopharma industry since 2009
Analysis of drug delivery deal structure and contract documents
Access to headline, upfront, milestone and royalty data
Case studies of real-life drug delivery deals
Access to over 2,000 drug delivery deals announced
The leading drug delivery deals by value since 2009
Most active drug delivery dealmakers since 2009
The leading drug delivery partnering resources
In Drug Delivery Partnering Terms and Agreements, the available contracts are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand."
To view the table of contents and know more details please visit Drug Delivery Partnering Terms and Agreements
The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 2,000 links to online copies of actual drug delivery deals and contract documents where available as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The drug delivery technology includes the following sub-technology areas:
Drug Delivery
Bioavailability
Implanatable
Oral delivery
Rapid release
Delayed release
Parenteral
Infusion
Injectable
Pro-drug
Targeted
Tropical
Transdermal
Buccal
Inhaled
Nasal
Ocular
Rectal
Sublingual
Urogenital
The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in drug delivery dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms. Chapter 2 also contains case studies providing an insight into how companies enter into drug delivery dealmaking.
Chapter 3 provides a review of the leading drug delivery deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and the contract document, providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of drug delivery partnering deals organized by specific drug delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in drug delivery partnering and dealmaking since 2009.
In addition, a comprehensive appendix is provided organized by drug delivery partnering company A-Z, deal type definitions and drug delivery partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of drug delivery technologies and products.
Drug Delivery Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to drug delivery trends and structure of deals entered into by leading companies worldwide.
Drug Delivery Partnering Terms and Agreements includes:
Trends in drug delivery dealmaking in the biopharma industry since 2009
Analysis of drug delivery deal structure and contract documents
Access to headline, upfront, milestone and royalty data
Case studies of real-life drug delivery deals
Access to over 2,000 drug delivery deals announced
The leading drug delivery deals by value since 2009
Most active drug delivery dealmakers since 2009
The leading drug delivery partnering resources
In Drug Delivery Partnering Terms and Agreements, the available contracts are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand."
To view the table of contents and know more details please visit Drug Delivery Partnering Terms and Agreements
No comments:
Post a Comment